Prosight Management, LP Buys Alexion Pharmaceuticals Inc, Direxion Small Cap Bear 3X Shares, Cue Biopharma Inc, Sells Arqule Inc, United Therapeutics Corp, Biomarin Pharmaceutical Inc

• New Purchases: ALXN, TZA, CHNG, LHCG, AMN, ZGNX, ADMA, ARWR, EHC, ESTA, ABBV, LGND, HCA, NSP, MITO, THC,
• Added Positions: CUE, IOVA, CI, KURA, ARNA, RETA, ALDX, ALBO, EOLS, MGTX, QURE, APEN, ORGO, PSNL, MIST,
• Reduced Positions: UTHR, BMRN, ZBH, NVST, ANAB, URGN, ACIU, KZR, CBIO,
• Sold Out: ARQL, SBBP, RCM, EVH, MTEM, PRTK, TNET, TLGT, BMY,

For the details of Prosight Management, LP's stock buys and sells, go to https://www.gurufocus.com/guru/prosight+management%2C+lp/current-portfolio/portfolio

1. Arena Pharmaceuticals Inc (ARNA) - 419,602 shares, 8.36% of the total portfolio. Shares added by 27.88%
2. Iovance Biotherapeutics Inc (IOVA) - 553,100 shares, 7.86% of the total portfolio. Shares added by 42.33%
3. Kura Oncology Inc (KURA) - 1,450,000 shares, 6.85% of the total portfolio. Shares added by 39.96%
4. Alexion Pharmaceuticals Inc (ALXN) - 140,000 shares, 5.97% of the total portfolio. New Position
5. uniQure NV (QURE) - 245,564 shares, 5.53% of the total portfolio. Shares added by 3.40%

Prosight Management, LP initiated holding in Alexion Pharmaceuticals Inc. The purchase prices were between $75.56 and $113.92, with an estimated average price of $98.6. The stock is now traded at around $100.92. The impact to a portfolio due to this purchase was 5.97%. The holding were 140,000 shares as of .

Prosight Management, LP initiated holding in Direxion Small Cap Bear 3X Shares. The purchase prices were between $32.83 and $105.52, with an estimated average price of $47.04. The stock is now traded at around $38.42. The impact to a portfolio due to this purchase was 3.52%. The holding were 125,000 shares as of .

Prosight Management, LP initiated holding in Change Healthcare Inc. The purchase prices were between $6.86 and $17.26, with an estimated average price of $14.09. The stock is now traded at around $10.68. The impact to a portfolio due to this purchase was 2.65%. The holding were 559,125 shares as of .

Prosight Management, LP initiated holding in LHC Group Inc. The purchase prices were between $104.81 and $158.93, with an estimated average price of $139.65. The stock is now traded at around $145.49. The impact to a portfolio due to this purchase was 2.32%. The holding were 34,909 shares as of .

Prosight Management, LP initiated holding in AMN Healthcare Services Inc. The purchase prices were between $48.28 and $81.99, with an estimated average price of $68.47. The stock is now traded at around $40.33. The impact to a portfolio due to this purchase was 2.29%. The holding were 83,471 shares as of .

Prosight Management, LP initiated holding in Zogenix Inc. The purchase prices were between $17.8 and $56.59, with an estimated average price of $36.87. The stock is now traded at around $26.30. The impact to a portfolio due to this purchase was 1.92%. The holding were 163,708 shares as of .

Prosight Management, LP added to a holding in Cue Biopharma Inc by 301.12%. The purchase prices were between $9.85 and $22.27, with an estimated average price of $16.16. The stock is now traded at around $25.62. The impact to a portfolio due to this purchase was 2.79%. The holding were 552,060 shares as of .

Prosight Management, LP added to a holding in Iovance Biotherapeutics Inc by 42.33%. The purchase prices were between $19.54 and $38.85, with an estimated average price of $26.44. The stock is now traded at around $35.37. The impact to a portfolio due to this purchase was 2.34%. The holding were 553,100 shares as of .

Prosight Management, LP added to a holding in Cigna Corp by 228.78%. The purchase prices were between $130.06 and $222.56, with an estimated average price of $194.84. The stock is now traded at around $184.46. The impact to a portfolio due to this purchase was 2.17%. The holding were 37,129 shares as of .

Prosight Management, LP added to a holding in Kura Oncology Inc by 39.96%. The purchase prices were between $6.45 and $14.04, with an estimated average price of $11.51. The stock is now traded at around $14.38. The impact to a portfolio due to this purchase was 1.96%. The holding were 1,450,000 shares as of .

Prosight Management, LP added to a holding in Arena Pharmaceuticals Inc by 27.88%. The purchase prices were between $34.83 and $54.15, with an estimated average price of $45.98. The stock is now traded at around $45.26. The impact to a portfolio due to this purchase was 1.82%. The holding were 419,602 shares as of .

Prosight Management, LP added to a holding in Aldeyra Therapeutics Inc by 42.50%. The purchase prices were between $1.62 and $6.4, with an estimated average price of $4.55. The stock is now traded at around $3.75. The impact to a portfolio due to this purchase was 0.71%. The holding were 2,035,340 shares as of .

Prosight Management, LP sold out a holding in Arqule Inc. The sale prices were between $19.96 and $20.04, with an estimated average price of $20.

Prosight Management, LP sold out a holding in Strongbridge Biopharma PLC. The sale prices were between $1.57 and $3.51, with an estimated average price of $2.6.

Prosight Management, LP sold out a holding in R1 RCM Inc. The sale prices were between $7.57 and $13.91, with an estimated average price of $12.08.

Prosight Management, LP sold out a holding in Evolent Health Inc. The sale prices were between $3.64 and $11.77, with an estimated average price of $9.01.

Prosight Management, LP sold out a holding in Molecular Templates Inc. The sale prices were between $11.31 and $18.26, with an estimated average price of $14.57.

Prosight Management, LP sold out a holding in Paratek Pharmaceuticals Inc. The sale prices were between $2.67 and $4.97, with an estimated average price of $3.69.